Cargando…
An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
The ability of clopidogrel (Plavix) to work in tandem with aspirin in a dual therapy strategy to boost the anti-platelet therapeutic impact and diminish platelet aggregation induced by platelet receptor inhibition is one of its many key advantages. The researchers discovered that the average reducti...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509004/ https://www.ncbi.nlm.nih.gov/pubmed/36171852 http://dx.doi.org/10.7759/cureus.28406 |
_version_ | 1784797140424327168 |
---|---|
author | Iskandar, Nicholas P Reddy, Akshay J Dang, Allen Ghauri, Muhammad S Min, Mildred Bachir, Mark Bachir, Alex Wagh, Himanshu Tak, Nathaniel Brahmbhatt, Hetal |
author_facet | Iskandar, Nicholas P Reddy, Akshay J Dang, Allen Ghauri, Muhammad S Min, Mildred Bachir, Mark Bachir, Alex Wagh, Himanshu Tak, Nathaniel Brahmbhatt, Hetal |
author_sort | Iskandar, Nicholas P |
collection | PubMed |
description | The ability of clopidogrel (Plavix) to work in tandem with aspirin in a dual therapy strategy to boost the anti-platelet therapeutic impact and diminish platelet aggregation induced by platelet receptor inhibition is one of its many key advantages. The researchers discovered that the average reduction in risk of adverse cardiovascular events related to Plavix much outweighed any potential systemic effects. The analysis also revealed that, even though treatment results for diabetic patients with coronary microvascular disease (CMD) are poorer, the dosage and administration of clopidogrel for dual therapy are not modified to address this issue. Although it has been established that the current standard of care for microvascular disease decreases damage, more study is necessary to ensure that this standard is enhanced. It may become more usual in the future to include patient groups in trials who do not have diabetes as a criterion. Patients with diabetes often have higher low-density lipoprotein (LDL) cholesterol levels than the general population, therefore, it is possible that the research findings are flawed. To confirm or reject this assumption, further research is necessary. |
format | Online Article Text |
id | pubmed-9509004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-95090042022-09-27 An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease Iskandar, Nicholas P Reddy, Akshay J Dang, Allen Ghauri, Muhammad S Min, Mildred Bachir, Mark Bachir, Alex Wagh, Himanshu Tak, Nathaniel Brahmbhatt, Hetal Cureus Cardiology The ability of clopidogrel (Plavix) to work in tandem with aspirin in a dual therapy strategy to boost the anti-platelet therapeutic impact and diminish platelet aggregation induced by platelet receptor inhibition is one of its many key advantages. The researchers discovered that the average reduction in risk of adverse cardiovascular events related to Plavix much outweighed any potential systemic effects. The analysis also revealed that, even though treatment results for diabetic patients with coronary microvascular disease (CMD) are poorer, the dosage and administration of clopidogrel for dual therapy are not modified to address this issue. Although it has been established that the current standard of care for microvascular disease decreases damage, more study is necessary to ensure that this standard is enhanced. It may become more usual in the future to include patient groups in trials who do not have diabetes as a criterion. Patients with diabetes often have higher low-density lipoprotein (LDL) cholesterol levels than the general population, therefore, it is possible that the research findings are flawed. To confirm or reject this assumption, further research is necessary. Cureus 2022-08-25 /pmc/articles/PMC9509004/ /pubmed/36171852 http://dx.doi.org/10.7759/cureus.28406 Text en Copyright © 2022, Iskandar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology Iskandar, Nicholas P Reddy, Akshay J Dang, Allen Ghauri, Muhammad S Min, Mildred Bachir, Mark Bachir, Alex Wagh, Himanshu Tak, Nathaniel Brahmbhatt, Hetal An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease |
title | An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease |
title_full | An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease |
title_fullStr | An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease |
title_full_unstemmed | An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease |
title_short | An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease |
title_sort | examination of clopidogrel in the treatment of coronary microvascular disease |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509004/ https://www.ncbi.nlm.nih.gov/pubmed/36171852 http://dx.doi.org/10.7759/cureus.28406 |
work_keys_str_mv | AT iskandarnicholasp anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT reddyakshayj anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT dangallen anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT ghaurimuhammads anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT minmildred anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT bachirmark anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT bachiralex anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT waghhimanshu anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT taknathaniel anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT brahmbhatthetal anexaminationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT iskandarnicholasp examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT reddyakshayj examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT dangallen examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT ghaurimuhammads examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT minmildred examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT bachirmark examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT bachiralex examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT waghhimanshu examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT taknathaniel examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease AT brahmbhatthetal examinationofclopidogrelinthetreatmentofcoronarymicrovasculardisease |